Literature DB >> 7252494

Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate.

C F MIlls, T T El-Gallad, I Bremner, G Weham.   

Abstract

Previous studies have shown that the tetrathiomolybdate ion [MoS4(2-)] is a potent antagonist of Cu metabolism. Effects of orally administered MoS4(2-) on the absorption and tissue distribution of 64Cu in rats have now been investigated. Four or 12 mg Mo/kg diet, when given as MoS4(2-), strongly inhibited 64Cu absorption and modified the fate of absorbed Cu, decreasing hepatic and renal uptake but increasing plasma retention of 64Cu. These effects were not induced by equivalent dietary concentrations of Mo as MoO4(2-) or when S2- was given as CaS. Clinical and biochemical effects induced by orally administered MoS4(2-) were abolished by increasing dietary concentrations of Cu. Such treatment also inhibited the absorption and tissue retention of 99Mo derived from 99MoS4(2-). Intraperitoneal administration of Cu ameliorated clinical effects attributable to MoS4(2-) but neither inhibited 99Mo absorption nor the appearance of systemic defects in Cu metabolism. Since the absorption of MoS4(2-) (or its derivatives) from the gastrointestinal tract is inhibited by Cu, it is evident that the site of its action as an antagonist influencing either the absorption or the subsequent metabolic fate of Cu depends upon the ratio Cu/MoS4(2-) in the diet.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252494     DOI: 10.1016/s0162-0134(00)80037-9

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  9 in total

1.  Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivo.

Authors:  Hao Wei; Balz Frei; Joseph S Beckman; Wei-Jian Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

Review 2.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

3.  Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis.

Authors:  Ming Song; Zhenyuan Song; Shirish Barve; Jingwen Zhang; Theresa Chen; Marcia Liu; Gavin E Arteel; George J Brewer; Craig J McClain
Journal:  J Pharmacol Exp Ther       Date:  2008-02-25       Impact factor: 4.030

Review 4.  Practical recommendations and new therapies for Wilson's disease.

Authors:  G J Brewer
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

5.  Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Andrew K Vine; George J Brewer
Journal:  Trans Am Ophthalmol Soc       Date:  2002

6.  Molybdenum-induced changes in the epiphyseal growth plate.

Authors:  N M Parry; M Phillippo; M D Reid; B A McGaw; D J Flint; N Loveridge
Journal:  Calcif Tissue Int       Date:  1993-09       Impact factor: 4.333

7.  Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.

Authors:  MengMeng Xu; Michael Casio; Danielle E Range; Julie A Sosa; Christopher M Counter
Journal:  Clin Cancer Res       Date:  2018-07-31       Impact factor: 13.801

8.  Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damage.

Authors:  Sabine Borchard; Stefanie Raschke; Krzysztof M Zak; Carola Eberhagen; Claudia Einer; Elisabeth Weber; Sandra M Müller; Bernhard Michalke; Josef Lichtmannegger; Albrecht Wieser; Tamara Rieder; Grzegorz M Popowicz; Jerzy Adamski; Martin Klingenspor; Andrew H Coles; Ruth Viana; Mikkel H Vendelbo; Thomas D Sandahl; Tanja Schwerdtle; Thomas Plitz; Hans Zischka
Journal:  Life Sci Alliance       Date:  2021-12-02

9.  Advance in the pathogenesis and treatment of Wilson disease.

Authors:  Qin-Yun Dong; Zhi-Ying Wu
Journal:  Transl Neurodegener       Date:  2012-11-27       Impact factor: 8.014

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.